Cancer pancreaticus in praesenti est inter carcinomata funestissima et chemotherapy-repugnantia. Nuper investigatores cancer in Australia elaboraverunt methodum nanometricam valde promittentem quae curatio cancri pancreatici emendabit.
Haec technologia medicamenta involvit quae specifica gena in nanoparticulis tacere possunt et ea ad tumores pancreaticos transferunt. Expectatur aegris cancer pancreaticum praebere cum alternatives ad curationes traditionales sicut chemotherapy.
Experiments conducted on mice showed that the new nanomedicine method reduced tuberculum growth by 50% and also slowed the spread of pancreatic cancer.
In investigationis published in Biomacromolecules dictitans deductusque ab University of Queensland a scientists (UNSW). Affert plerisque pancreaticum cancer aegros spem superesse non possunt 3-6 menses diagnosi.
Dr. Phoebe Phillips a UNSW Roy Cancer Research Centre (Lowy Cancer Research Centre) erat principale qui studiorum praepositus erat. Dixit medicus, quoties collegae suos aegros cancer pancreatis informare debebant, Etiamsi optima medicamenta chemotherapy adiuvant ut vitam suam extendant per XVI septimanas, doctores quidem valde intolerabiles sunt.
Dr Phillips dixit: “Praecipua ratio quare chemotherapy non operatur est quod tumores pancreatici in cicatrice cicatricis amplis habent, quod rationem 90% totius tumoris habere potest. Cicatrix texti facit obice physicum prohibens medicamenta tumorem attingere, cancer pancreaticus causans. Cellulae chemotherapy repugnant. "
She explained: “Recently, we have discovered a key gene that promotes the growth, spread and resistance of pancreaticum cancer-βIII-tubulin. Inhibiting this gene in mice not only reduced tumor growth by half, It also slows down the spread of cancer cells. “
Nihilominus, ut hoc genus amet supprimendum, difficultas administrationis medicamentorum superanda est: traiectionem cicatricis tumorum pancreaticorum. Ad hanc quaestionem solvendam, investigatores Australiae instrumenti medicae nano-medici elaboraverunt, moleculae RNA (ut exemplum DNA cellularum intelligi possunt) in nano-particulis progressis involutae, hae RNA moleculae ad tumorem perveniunt postquam potest ad magna ex parte, inhibere βIII-tubulin gene.
Hi investigatores facultatem novorum nanoparticulorum in muribus demonstraverunt. Earum nanoparticulae medicatae microRNA doses medicinales ad tumores pancreaticos in muribus coram texti cicatricis liberare possunt, et βIII-tubulin feliciter inhibent.
« Significatio technologiae nanomedicinae nostrae est quod expectatur ad omnem tumorem promovendi genem supprimendam, vel generum copiae quae 'privatae nativus' secundum expressionem tumoris gene. Dr. Phillips dixit.
"Hoc factum auxiliatus develop novum populo huic medicamento repugnant cancer treatments et augendae efficaciam ex existentium chemotherapy modi est, ita qualis est vita melius superessendam rate et pancreaticum cancer aegris."
